In a prospective multicenter cohort study with 1650 anti-TNF-α naïve patients with active luminal Crohn’s disease (CD), the authors have concluded that anti-TNF-α treatment failure is common and can be predicted by low drug concentrations mediated in part by immunogenicity [5]. This evidence concerns the gene TNF and Cowden disease.